How much funding has Septerna raised?

Septerna has raised $250.0M in total funding, most recently a Series B round.

Who are Septerna's investors?

Septerna's investors include Third Rock Ventures, RA Capital Management, Samsara BioCapital, BVF Partners, Catalio Capital Management, Casdin Capital.

Where is Septerna headquartered?

Septerna is headquartered in South San Francisco, California, United States.

What industry is Septerna in?

Septerna operates in Biotechnology, Healthcare.

Septerna

IPO

Pioneering a new era of GPCR drug discovery

Public · South San Francisco, United States · Founded 2022 · $250.0M raised

Biotechnology

Healthcare

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2022
Business Model: B2B
Website: septerna.com

Total Funding: $250.0M
Last Round: $150.0M Series BJul 2023
Rounds: 2
Type: Public

About

Septerna is a biotechnology company powered by its proprietary Native Complex Platform, designed to unlock the full potential of G protein-coupled receptors (GPCRs) — the most prolific drug target class. The company is building a deep pipeline of oral small molecule product candidates across three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Co-founded by Nobel laureate Robert Lefkowitz and CEO Jeffrey Finer, Septerna launched in January 2022 with a $100 million Series A backed by Third Rock Ventures. The company is headquartered at 250 East Grand Avenue, South San Francisco, CA.

Summary

Septerna is a Biotechnology company based in South San Francisco, United States, founded in 2022. It has raised $250.0M in total across 2 rounds, most recently a $150.0M Series B round in Jul 2023. Investors include Third Rock Ventures, RA Capital Management and Samsara BioCapital.

LinkedIn X (Twitter)